Benzinga | Apr 23, 2021 07:02AM EDT

ProQR Therapeutics To Present Data From Co.'s Phase 1/2 InSight Extension Trial Of Sepofarsen At Association For Research In Vision And Ophthalmology May 6, 2021 At 5:15 p.m. EDT

ProQR Therapeutics N.V. (NASDAQ:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual oral presentation of data from the Company's Phase 1/2 InSight extension trial of sepofarsen and live Q&A session at the Association for Research in Vision and Ophthalmology (ARVO) held May 1-7, 2021. This is an encore presentation of the InSight study data that was presented during the Expert Perspectives Call in July 2020. We expect to present new data from the InSight study in H2 2021.

ProQR's Presentation

Presentation title: Safety and efficacy of sepofarsen in the second treated eye in a Ph1b/2 extension trial in Leber Congenital Amaurosis type 10 (LCA10)

Presenter: Stephen R. Russell, MD, Professor and Director of Vitreoretinal Diseases and Surgery Service, Department of Ophthalmology and Visual Sciences, University of Iowa

Presentation type: Oral paper presentation followed by a live Q&A session.

Session: Stem cells/gene therapy/transplantation

Date: May 6, 2021 at 5:15pm EDT